Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study

By afschroeder • July 29, 2026

McLaughlin VV, Solum D, Lachant D, Ataya A, Barberà JA, Meyer GB, Chang SA, Channick R, Church C, Feenstra J, Gaine S, Giannakoulas G, Jerjes-Sanchez C, Khanna D, Kim NH, Oudiz R, Preston IR, Sood N, Torres F, Vachiery JL, Pulido T, Cella D, Deng C, Escudero M, Lacasse V, Peterson L, Benza R, Humbert M; ADVANCE OUTCOMES Investigators. Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study. Lancet. 2026 Jul 28:S0140-6736(26)01011-1. doi: 10.1016/S0140-6736(26)01011-1. Epub ahead of print. PMID: 42520828.

Tags: Publications, Pulmonary, Critical Care & Sleep Medicine

Related Posts

Development of a Primary Care Cardio-Kidney Risk Navigator for Clinical Decision Support

Gluckman TJ, Birkeland K, Bhatt A, Budoff MJ, Danna SC, Desai NR, Norfolk E, Elbedewe A, Kiernan G, Pachpor R, Hirsch J. Development of a[...]

Closing the completion colonoscopy gap: key takeaways from the American Society for Gastrointestinal Endoscopy’s 2025 National Colorectal Cancer Screening Summit

Hosseini-Carroll P, Dominitz JA, Jacobson BC, May FP, Issaka RB, Schmitt CM, Adams TL, Boston IJ, Bucobo JC, Day L, Khaykis IB, Marino MJ, Rex[...]

Hidden risk in normal myocardial perfusion scans: AI-detected proximal coronary calcium on CT attenuation maps improves prognosis

Zhou J, Miller RJH, Shanbhag A, Killekar A, Han D, Patel KK, Pieszko K, Yi J, Urs MK, Ramirez G, Lemley M, Kavanagh PB, Liang[...]